Vyndaqel is an English word starting with the letter V. With 2 example sentences you'll see exactly how it works in context.
Vyndaqel in a sentence
Context around Vyndaqel
- Average sentence length in these examples: 24 words
- Position in the sentence: 0 start, 1 middle, 1 end
- Sentence types: 2 statements, 0 questions, 0 exclamations
Corpus analysis for Vyndaqel
- In this selection, "vyndaqel" usually appears in the middle of the sentence. The average example has 24 words, and this corpus slice is mostly made up of statements.
- Around the word, eliquis and inlyta stand out and add context to how "vyndaqel" is used.
- Recognizable usage signals include tafamidis or vyndaqel a kinetic and xeljanz eliquis vyndaqel inlyta and. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "vyndaqel" sits close to words such as aabb, aabria and aacha, which helps place it inside the broader word index.
Example types with vyndaqel
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
Revenues with the Pfizer Biopharmaceuticals Group grew 9% operationally versus the year ago quarter, driven by Ibrance, Xeljanz, Eliquis, Vyndaqel, Inlyta and Xtandi. (23 words)
Recently the European Medicines Agency approved the use of Tafamidis or Vyndaqel (a kinetic stabilizer of tetrameric transthyretin) for the treatment of transthyretin amyloid diseases. (25 words)
Recently the European Medicines Agency approved the use of Tafamidis or Vyndaqel (a kinetic stabilizer of tetrameric transthyretin) for the treatment of transthyretin amyloid diseases. (25 words)
Revenues with the Pfizer Biopharmaceuticals Group grew 9% operationally versus the year ago quarter, driven by Ibrance, Xeljanz, Eliquis, Vyndaqel, Inlyta and Xtandi. (23 words)
Example sentences (2)
Revenues with the Pfizer Biopharmaceuticals Group grew 9% operationally versus the year ago quarter, driven by Ibrance, Xeljanz, Eliquis, Vyndaqel, Inlyta and Xtandi.
Recently the European Medicines Agency approved the use of Tafamidis or Vyndaqel (a kinetic stabilizer of tetrameric transthyretin) for the treatment of transthyretin amyloid diseases.